Vera Therapeutics, Inc.

NASDAQ:VERA

Biotechnology

Healthcare
$26.75 +0.27%

+$0.09 today

Market cap
$1.93B
Beta
0.95
P/E (TTM)
-6.8
EPS (TTM)
-$5.16
52W Low $19.07High $56.05

Volume 1.05M

Average 1.18M

Returns on capital

Vera Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-49.6%

avg -34.4%

ROIC

-46.3%

avg -89.8%

ROA

-40.8%

avg -77.7%

Analysis

ROA is currently the strongest return metric at -40.8% versus its period average of -77.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Marshall Fordyce

Founder, President, Chief Executive Officer & DirectorUSD 1.21M51235.24K0.33%

David L. Johnson

Chief Opearating OfficerUSD 798.6K56——

Robert Brenner

Chief Medical OfficerUSD 797.04K5850.95K0.07%

Sean Grant

Chief Financial OfficerUSD 793.92K41114.18K0.16%

Jane Wright-Mitchell

Chief Legal Officer & Secretary—570<0.01%

Tom Doan

Executive Vice President of Development Operations—54——

Debra Charlesworth

Vice President of Corporate Communications————

Emma Haywood

Vice President of Marketing————

S. Sandra Park

Senior Vice President of Legal, Healthcare,Commercial Law, Compliance & Operations————

Joseph R. Young

Senior Vice President of Finance & Chief Accounting Officer—5433.59K0.05%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 15, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$249,985.00

Sells

32

$11.89M

Net Transaction Value

−$11.64M

Net selling

Most Active

Fordyce Marshall

22 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 15, 26

Fordyce Marshall

Direct

Sell$684.5K
Sep 2, 26

Fordyce Marshall

Direct

Sell$649.6K
Jul 7, 26

Fordyce Marshall

Direct

Sell$450K
Jul 7, 26

Fordyce Marshall

Direct

Sell$40.8K
Jul 7, 26

Fordyce Marshall

Direct

Sell$1.4M
Jul 7, 26

Fordyce Marshall

Direct

Sell$450K
Jul 7, 26

Fordyce Marshall

Direct

Sell$95.9K
Jul 7, 26

Fordyce Marshall

Direct

Sell$40.8K
Jul 7, 26

Fordyce Marshall

Direct

Sell$1.4M
Jul 7, 26

Fordyce Marshall

Direct

Sell$95.9K

1–10 of 33

Summary

Insiders reported 1 buys worth $249,985.00 and 32 sells worth $11.89M over the last 12 months. That adds up to net selling of $11.64M. Fordyce Marshall was the most active insider with 22 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A6 analysts
RevenueN/AN/AN/A
N/A4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Vera Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about VERA's management, answered from reported figures.

Who manages VERA?

Vera Therapeutics, Inc. (VERA) lists 10 active executives. The top listed executive is Jane Wright-Mitchell, Chief Legal Officer & Secretary.

Are VERA insiders buying or selling?

Recent insider activity shows net buying of $32.43M.